Approved CAR-T therapies have reproducible efficacy and safety in clinical practice

Autor:	Daniel Goyco Vera, Hiral Waghela, Mohamed Nuh, Jonathan Pan, Premal Lulla
Jazyk:	angličtina
Rok vydání:	2024
Předmět:	CAR-T CAR-T efficacy CAR-T safety CAR-T outcomes CAR-T real-world chimeric antigen receptor T-cell therapy outcomes Immunologic diseases. Allergy RC581-607 Therapeutics. Pharmacology RM1-950
Zdroj:	Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
Druh dokumentu:	article
ISSN:	21645515 2164-554X 2164-5515
DOI:	10.1080/21645515.2024.2378543
Popis:	CAR-T cell therapy has established itself as a highly effective treatment for hematological malignancies. There are currently six commercial CAR-T products that have been FDA approved for diseases such as B-ALL, LBCL, MCL, FL, MM, and CLL/SLL. “Real-world” studies allow us to evaluate outcomes from the general population to determine their efficacy and safety compared to those who were included in the original trials. Based on several well conducted “Real-world” studies that represent diverse populations, we report that outcomes from the original trials that led to the approval of these therapies are comparable to those in practice.
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/8be1593749b242ad99804b17561ed3a1 Zobrazit plný text záznamu View record in DOAJ